erlotinib hydrochloride has been researched along with olaparib in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Shi, C; Sui, H; Yan, Z | 1 |
| Dikomey, E; Gleißner, L; Hoffer, K; Kriegs, M; Kwiatkowski, M; Myllynen, L; Petersen, C; Riepen, B; Rothkamm, K; Schlüter, H; Wurlitzer, M | 1 |
2 other study(ies) available for erlotinib hydrochloride and olaparib
| Article | Year |
|---|---|
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; BRCA1 Protein; BRCA2 Protein; Cadaverine; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1.
Topics: Carcinoma, Squamous Cell; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteomics; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Tumor Suppressor p53-Binding Protein 1 | 2015 |